Founder-CEO Interview Series
Sejelas Read more
Disease-modifying treatment for ALS enters Phase I
Drug Discovery World Read more
Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical Trial
Target ALS Read more
Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical Trial – Target ALS
ALS News Today Read more
NRG doses first volunteers in mitochondrial ALS trial
Longevity Technology Read more
Michael J Fox Foundation adviser joins NRG Therapeutics
Business Weekly Read more
NRG Therapeutics expands team with CDO appointment
thepharmaletter Read more
NRG Therapeutics appoints Paul Thompson as CDO
Drug Discovery World Read more
© NRG Therapeutics
